Most ‘GLP-1 Nonresponders’ Never Get a Fair Shot
I see this pattern every week. A patient is 12 weeks into semaglutide therapy. They’ve lost 2%-3% of…
Most GLP-1 Prescriptions Miss the Mark: Are Yours?
GLP-1 receptor agonists, including semaglutide, are now widely used for weight loss, offering substantial weight reduction, improved metabolic…
GLP-1 RAs Protective Against Stroke, Neurodegeneration?
TOPLINE: Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly semaglutide and tirzepatide, was associated with a…